Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Commercial identity or variant awaiting clarification.
Mechanism
Commercially described C-terminal GH fragment; equivalence with AOD-9604 must not be assumed.
Evidence and critical reading
Reported scientific and empirical uses
Reported weight management
Promoted for lipolysis/fat reduction. A fragment and a sequence modification require separate records.
Human evidence
The search retrieved fragment/nanoparticle experiments, not a confirmatory fat-loss trial for this vial. Do not import somatropin or AOD regimens.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
The search retrieved fragment/nanoparticle experiments, not a confirmatory fat-loss trial for this vial. Do not import somatropin or AOD regimens.
The search retrieved fragment/nanoparticle experiments, not a confirmatory fat-loss trial for this vial. Do not import somatropin or AOD regimens.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Commercially claimed absence of somatotropic effects does not demonstrate human safety; exact-material characterization is missing.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
HGH fragment 176–191 · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID35783198
Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA.
October 16, 2026
- R04
- SEARCH-PUBMED-hgh-fragment-176-191
PubMed/MED targeted search: TITLE_ABS:"176-191" AND TITLE_ABS:human
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026